| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.09% | 85.57% | 75.51% | — | — | — | — | — |
| Operating Margin | -91.36% | -502.18% | -24532.55% | — | — | — | — | — |
| EBITDA Margin | -91.00% | -500.75% | -24448.24% | — | — | — | — | — |
| Net Margin | -126.35% | -605.09% | -29558.94% | — | — | — | — | — |
| Current Ratio | 1.73 | 4.20 | 10.25 | 6.12 | 9.86 | 5.25 | 68.20 | 0.41 |
| Quick Ratio | 1.69 | 4.16 | 10.22 | 6.12 | 9.86 | 5.25 | 68.20 | 0.41 |
| Debt / Equity | -0.48 | -0.79 | -1.89 | -1.27 | 1.24 | 0.24 | 0.10 | — |
| ROE | 50.49% | 131.84% | 277.07% | 264.29% | -199.41% | -66.44% | -111.92% | 100.16% |
| ROA | -85.37% | -88.37% | -48.71% | -119.97% | -75.96% | -43.74% | -99.20% | -142.79% |
| Asset Turnover | 0.68 | 0.15 | 0.00 | 0.00 | — | — | — | — |
| Book Value / Share | -6.01 | -4.01 | -1.42 | -1.91 | 1.95 | — | — | — |
Phathom Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases related to acid. Its flagship product, VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, is approved for adults with erosive gastroesophageal reflux disease (GERD) and heartburn, as well as non-erosive GERD. The company also offers VOQUEZNA Triple Pak and VOQUEZNA Dual Pak combination therapies for treating Helicobacter pylori infections. These products address key unmet needs in the GI sector by providing superior acid suppression compared to traditional proton pump inhibitors. Phathom Pharmaceuticals Inc. emphasizes commercializing these therapies in the United States, supported by ongoing clinical data presentations at medical conferences and prescription growth tracking. Founded in 2018 and headquartered in Florham Park, New Jersey, the company plays a significant role in advancing innovative GI treatments within the biopharmaceutical market.